Dexcom and IQVIA: product management, strategy, negotiations, and CGM research
Led CGM product management, strategy, Dexcom licensing negotiations, and IQVIA vendor management. The Dexcom-related Rarify mobile and cloud components did not enter production but created a credible IQVIA replacement threat. Kevin reports that IQVIA’s Dexcom sensor data contributed to evidence supporting FDA accelerated approval of Genglycos (DTX401) for GSDIa.
Ultragenyx · 2019–2024; subsequent approval milestone · 2026